drugset / Trial / NCT02840279

A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects

NCT02840279

Phase 1 Completed 77 enrolled Tetra Discovery Partners
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind (Investigator and subject-blinded) placebo-controlled, multiple, ascending-dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy young and elderly male and female subjects and to provide a preliminary assessment of the cognitive effects of BPN14770 in healthy elderly subjects.

Timeline

Start
2016-06
Primary completion
2016-11
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject zatolmilast Small molecule Oral

Indications